March 07, 2026 12:59 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Sensex, Nifty tumble as global tensions and Dow selloff rattle Indian markets | Two IAF pilots killed as Su-30MKI fighter jet crashes in Assam | 'Who is the US to permit?': Congress slams Modi govt over Trump administration’s waiver on India’s Russian oil purchase | US makes surprise move: India gets 30-day waiver to buy Russian oil amid global supply crisis | India edge England by 7 runs in thriller to reach T20 World Cup 2026 final | 'Guest of India struck in international waters': Iran furious after US submarine torpedoes IRIS Dena | Bihar's 'Susashan Babu' Nitish Kumar announces exit as CM, set for Rajya Sabha debut | ‘Baseless’: India rejects claims US used its ports to strike Iran | Defiant silence: Iran women’s team refuses anthem days after Khamenei’s death | 'You’ll find out soon': Trump hints at massive retaliation after Riyadh attack, says ‘boots on ground’ may not be needed

Aurobindo Pharma receives USFDA approval for drug related to moderate dementia

| | Mar 29, 2016, at 08:16 pm
Hyderabad/Mumbai, Mar 29 (IBNS) Aurobindo Pharma Limited, which manufactures generic pharmaceuticals and active pharmaceutical ingredients, announced on Tuesday that the company has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Rivastigmine Tartrate Capsules USP, 1.5 mg, 3 mg, 4.5 mg and 6 mg.
This product is expected to be launched in the first quarter of fiscal year 2016-17.
 
The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Exelon Capsules, 1.5 mg, 3 mg, 4.5 mg and 6 mg, of Novartis Pharmaceuticals Corporation, said the company.
 
Naproxen Sodium Tablets is used in the treatment of mild moderate dementia of the Alzheimer's and Parkinson's disease. 
 
The approved product has an estimated market size of US$ 26.7 million for the twelve months ending January 2016 according to IMS.
 
This is the 67th ANDA (including 14 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing oral non-antibiotic products. 
 
Aurobindo now has a total of 246 ANDA approvals (211 Final approvals including 10 from Aurolife Pharma LLC and 35 tentative approvals) from USFDA.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm